Barely Significant
← all excerpts

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.

Commun Med (Lond) · 2022 · PMC9424215 · PMID 36051466

Europe PMCDOI
1
hedged sentence
0.0050
closest p · 0.1× alpha
0.0050
boldest claim

The sentences

highly significantp = 0.005actually significant
5E ) and RFS difference between Vigil and placebo was highly significant in this population (median not reached vs 11.8 months, HR = 0.21, p = 0.005) (Fig. 5F ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.